WuXi Biologics grants restricted shares under award scheme

WuXi Biologics (Cayman) Inc. has announced the grant of 64,117 Restricted Shares under its Restricted Share Award Scheme, effective June 5, 2025. The shares are granted to one employee of the Group, considered an independent third party to the Company. The purchase price for the RSA Restricted Shares is nil. The market price of the shares on the grant date is HK$24.90 per share. Vesting will occur over five years, with 20% vesting on each of the second, third and fourth anniversaries of the grant date, and the remaining 40% vesting on the fifth anniversary. The announcement details clawback mechanisms and confirms that no specific performance targets are attached to this grant beyond the time-based vesting schedule. Following this grant, 187,681,267 Restricted Shares remain available for future grants under the Scheme Mandate Limit.